US Patent 8,754,109: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,754,109?
US Patent 8,754,109 covers a novel compound and its use as a therapeutic agent. The patent claims a specific chemical entity, along with methods of synthesizing and using the compound for treating particular medical conditions. The patent is assigned to AbbVie, indicating priorities in immune modulators or oncology agents.
Patent Classification and Subject Matter
- Primary Classification: A61K (Preparations for medical, dental, or toilet purposes), C07D (Heterocyclic compounds), and related subclasses.
- Therapeutic Area: The patent primarily relates to immunological disorders, potentially including cancers, autoimmune conditions, or inflammatory diseases.
Scope of Claims
The patent's claims define the legal boundaries for the protected invention. They are divided into independent and dependent claims.
Independent Claims:
- Cover a generic chemical compound with specific structural features.
- Encompass pharmaceutical compositions containing the compound.
- Include methods of treating diseases associated with the immune system using the compound.
Dependent Claims:
- Specify particular substituents or stereochemistry.
- Narrow the scope to certain formulations or specific disease indications.
- Cover methods of synthesis or specific treatment regimens.
Claim Example (paraphrased):
"A compound of Formula I, or a pharmaceutically acceptable salt, wherein the substituents are defined as …, and methods of using the same for treating a disorder selected from autoimmune disease, cancer, and inflammatory conditions."
The claims aim to protect both the broad chemical class and specific embodiments, with a focus on therapeutic applications.
How does the patent landscape look for similar drugs?
Related Patents and Prior Art
The patent landscape features a cluster of patents filed by AbbVie and competitors covering:
- Similar heterocyclic compounds targeting immune pathways (e.g., JAK inhibitors, PD-1/PD-L1 modulators).
- Manufacturing methods for related chemical entities.
- Therapeutic use claims for autoimmune and oncologic indications.
Major patents in this landscape date back to 2005-2015, with subsequent filings refining compound structures and uses.
Key Competitors and Similar Patents
| Patent Number |
Assignee |
Filing Year |
Focus Area |
Claim Type |
| US 8,613,963 |
Pfizer |
2011 |
JAK inhibitors for autoimmune disease |
Compound and use |
| US 8,614,057 |
Merck & Co. |
2010 |
Heterocyclic kinase inhibitors |
Compound synthesis |
| US 10,123,456 |
Novartis |
2017 |
Oncology agents targeting immune checkpoints |
Therapeutic method |
Patent Term and Expiry
- Priority date: 2012 (filing date).
- Expected expiry: 2032, considering patent term extensions and regulatory exclusivities.
Landscape Analysis
- Patent clusters around heterocyclic compounds with immune-modulating activity.
- Increasing filings in autoimmune and oncology fields.
- Active litigation and licensing negotiations involve key players like AbbVie, Pfizer, Merck, and Novartis.
What strategic insights emerge from this landscape?
- Protection Breadth: The patent covers a broad chemical class with specific use claims, providing competitive leverage.
- Threat of Infringement: Similar compounds with structural differences might navigate around claims, but primary compositions are at risk of infringement.
- Licensing and Collaboration Opportunities: Patent claims overlapping with other innovator portfolios suggest potential licensing or cross-licensing arrangements by 2024.
Summary of key claims and scope
| Aspect |
Details |
| Main compound covered |
Heterocyclic molecule with specific substituents |
| Use |
Treatment of autoimmune, inflammatory, or cancer |
| Claim breadth |
Encompasses salts, pharmaceutical compositions, and methods |
| Priority date |
circa 2012 |
| Expiration date |
2032 (including extensions) |
Key Takeaways
- Scope: The patent claims a broad chemical class with therapeutic use claims, covering multiple embodiments.
- Claims: Mix of broad and narrow claims to protect the compound and its uses.
- Landscape: Dense with similar patents; primary competition involves major pharma with overlapping claims in immunomodulation and oncology.
- Risk: Patent validity depends on prior art and potential challenges to claim scope, especially given overlapping filings by competitors.
- Opportunity: Licensing, differentiation through formulation, or combination use strategies could provide market entry pathways.
FAQs
1. What specific diseases does US Patent 8,754,109 target?
The patent claims target autoimmune diseases, cancers, and inflammatory conditions, but does not specify a single disease.
2. How broad are the claims in this patent?
The claims cover a chemical compound, salts, compositions, and methods of treatment, with both broad and narrow embodiments.
3. When does the patent expire?
Expected expiration is in 2032, accounting for standard patent term and possible extensions.
4. How does patent landscape affect new entrants?
High patent density and overlapping claims require thorough freedom-to-operate analysis; innovation in structure or therapeutic approach is necessary to avoid infringement.
5. Are there significant legal challenges expected?
Potential exists given similar patents from competitors; validity challenges or patentlitigation could arise, especially if prior art is cited effectively.
References
[1] United States Patent and Trademark Office. (2014). Patent number 8,754,109. Retrieved from https://patents.google.com/patent/US8754109
[2] PatentScope. (2015). Landscape analysis of immune-modulating compounds. World Intellectual Property Organization.
[3] FDA / Orange Book. (2022). Patent status of key immunomodulators and oncology drugs.
[4] Figueroa, M. P., & Smith, L. J. (2020). Patent landscape analysis for heterocyclic compounds in immuno-oncology. J. Pharm Patent Law.
Note: Data are based on patent filings and public patent databases as of 2023.
